News: UnitedHealth Group Inc (UNH)

UNH on New York Consolidated

118.01USD
27 Mar 2015
Change (% chg)

-- (--)
Prev Close
$118.01
Open
--
Day's High
--
Day's Low
--
Volume
16,863
Avg. Vol
4,132,438
52-wk High
$121.53
52-wk Low
$73.61

Search Stocks
Select another date:

US STOCKS-Futures point to higher open on M&A activity

* M&A deal lifts sentiment; UnitedHealth unit to buy Catamaran

UnitedHealth to buy pharmacy benefit firm Catamaran for $12.8 billion

- Health insurer UnitedHealth Group agreed to buy Catamaran Corp in a deal worth about $12.8 billion to boost its pharmacy benefit business as it competes with bigger rivals such as Express Scripts Holdings Co.

UPDATE 2-UnitedHealth to buy pharmacy benefit firm Catamaran for $12.8 bln

March 30 - Health insurer UnitedHealth Group agreed to buy Catamaran Corp in a deal worth about $12.8 billion to boost its pharmacy benefit business as it competes with bigger rivals such as Express Scripts Holdings Co.

US STOCKS-Futures higher, but crude oil weakens

* M&A deal lifts sentiment; UnitedHealth unit to buy Catamaran

UnitedHealth Group to buy Catamaran for $12.78 bln

March 30 - UnitedHealth Group unit OptumRx Corp agreed to buy pharmacy benefit manager Catamaran Corp in a deal worth $12.78 billion.

UnitedHealth places tighter controls on hysterectomies

- UnitedHealth Group Inc, the largest health insurer in the United States, is placing tighter controls on its coverage of hysterectomies after a device called a morcellator was linked to the spread of undiagnosed cancer cells.

UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

- UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.

UPDATE 2-UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

Jan 28 - UnitedHealth Group Inc, the largest U.S. health insurer, on Wednesday backed Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list, another victory for Gilead over competitor AbbVie Inc.

UnitedHealth backs Gilead's Harvoni as preferred hepatitis C treatment

Jan 28 - UnitedHealth Group Inc on Wednesday backed Gilead Sciences Inc's hepatitis C treatment Harvoni on its 2015 commercial drug coverage list over a new competitor, Viekira Pak from AbbVie Inc.

Wall Street up on ECB bets but details, IBM cap gains

NEW YORK - U.S. stocks edged up in a choppy Wednesday session as traders digested reports that new stimulus would be announced by the European Central Bank at its Thursday meeting, while declines in IBM limited gains.

Select another date:
Search Stocks